Catalent Pharma Solutions

Catalent is a global leader in enabling pharma, biotech and consumer health partners to optimise product development, launch and full lifecycle supply for patients around the world.

With broad and deep scale and expertise in development sciences, delivery technologies and multi-modality manufacturing, Catalent is an industry partner for personalised medicines, consumer health brand extensions and blockbuster drugs.

Catalent helps accelerate over 1,500 partner development programmes and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion unit doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 17,000 includes more than 3,000 scientists and technicians.

The company generated approximately US$4.4 billion (£3.3 billion) in revenue in its 2024 fiscal year.

In February 2024, Novo Holdings A/S (the Novo Nordisk Foundation’s wholly owned holding company) agreed to acquire Catalent for US$16.5 billion.